Orchard Therapeutics plc
Orchard Therapeutics plc (ORTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
ortx · stock forecast · 10 analysts (3M) · FMP · updated May 1, 2024
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $16.70
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ORTX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-10-05 | Stifel | Downgrade ↓ | Buy→Hold |
| 2023-10-04 | Stifel | Downgrade ↓ | Buy→Hold |
| 2023-08-09 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-08-08 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-06-27 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-06-26 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-06-13 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-06-12 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-03-28 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-03-27 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Orchard Therapeutics plc (ORTX) stock. Of the recent 27 rating actions, 1 were upgrades and 7 were downgrades. 10 analysts currently cover ORTX.
Analyst Recommendation Trends
ORTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$8M
↓ 63.8% YoY
Revenue Next Year
$21M
↑ 169.1% YoY
EPS This Year
$-12.10
EPS Next Year
$-5.80
↓ 52.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast ORTX EPS of $-12.10 for the current fiscal year, based on estimates from 0 analysts. The ORTX revenue forecast is $8M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ORTX stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ORTX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
Orchard Therapeutics plc trades on NASDAQ under the ticker ORTX. The ORTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.
Frequently asked questions
ORTX forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month ORTX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $16.70.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.